Metoclopramide : A Template for Drug Discovery
@inproceedings{Sanger2017MetoclopramideA,
title={Metoclopramide : A Template for Drug Discovery},
author={G. Sanger},
year={2017}
}Metoclopramide was described in 1964 as an anti-emetic drug and stimulant of gastrointestinal motility. Dopamine D2 receptor antagonism explained the anti-emetic activity and was suggested to stimulate gastrointestinal motility. An important use of metoclopramide and other D2 receptor antagonists is to inhibit emesis caused by anticancer chemo radiotherapy. However, the use of new platinum-based anti-cancer drugs led to debilitating emesis, lasting for days and sometimes leading to refusal of… CONTINUE READING
One Citation
A History of Drug Discovery for Treatment of Nausea and Vomiting and the Implications for Future Research
- Medicine
- Front. Pharmacol.
- 2018
- 26
- PDF
References
SHOWING 1-10 OF 72 REFERENCES
Evidence that 5-hydroxytryptamine3 receptors mediate cytotoxic drug and radiation-evoked emesis.
- Medicine
- British Journal of Cancer
- 1987
- 120
- PDF
Translating 5‐HT4 receptor pharmacology
- Medicine, Chemistry
- Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society
- 2009
- 53
Metoclopramide. An updated review of its pharmacological properties and clinical use.
- Medicine
- Drugs
- 1983
- 329
Clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics
- Medicine
- Alimentary pharmacology & therapeutics
- 2004
- 216
Molecular mechanisms of 5-HT(3) and NK(1) receptor antagonists in prevention of emesis.
- Medicine
- European journal of pharmacology
- 2014
- 93
5-hydroxytryptamine m-receptor antagonism to prevent cisplatin-induced emesis
- Medicine
- Neuropharmacology
- 1986
- 180